Technical Analysis for VYNE - VYNE Therapeutics Inc. - Common Stock
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical VYNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | -3.19% | |
| Inside Day | Range Contraction | -3.19% | |
| Wide Bands | Range Expansion | -3.19% | |
| Oversold Stochastic | Weakness | -3.19% | |
| Lower Bollinger Band Walk | Weakness | -3.02% | |
| Wide Bands | Range Expansion | -3.02% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Trending on StockTwits | about 6 hours ago |
| Down 3% | about 17 hours ago |
| Lower Bollinger Band Support | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Down 2 % | about 19 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/05/2020
VYNE Therapeutics Inc. - Common Stock Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Autoimmune Diseases Psoriasis Dermatology Dermatitis Acne Atopic Dermatitis Rosacea Pruritus Acne Vulgaris Prurigo Prurigo Nodularis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.1624 |
| 52 Week Low | 4.84 |
| Average Volume | 1,754,951 |
| 200-Day Moving Average | 7.12 |
| 50-Day Moving Average | 7.84 |
| 20-Day Moving Average | 6.60 |
| 10-Day Moving Average | 6.19 |
| Average True Range | 0.46 |
| ADX | 41.55 |
| +DI | 8.60 |
| -DI | 33.58 |
| Chandelier Exit (Long, 3 ATRs ) | 6.48 |
| Chandelier Exit (Short, 3 ATRs ) | 6.75 |
| Upper Bollinger Band | 7.82 |
| Lower Bollinger Band | 5.38 |
| Percent B (%b) | 0.03 |
| BandWidth | 37.04 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.43 |
| MACD Histogram | -0.0839 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.97 | ||||
| Resistance 3 (R3) | 6.00 | 5.86 | 5.89 | ||
| Resistance 2 (R2) | 5.86 | 5.73 | 5.84 | 5.86 | |
| Resistance 1 (R1) | 5.66 | 5.65 | 5.59 | 5.63 | 5.83 |
| Pivot Point | 5.52 | 5.52 | 5.48 | 5.50 | 5.52 |
| Support 1 (S1) | 5.32 | 5.39 | 5.25 | 5.29 | 5.09 |
| Support 2 (S2) | 5.18 | 5.31 | 5.16 | 5.06 | |
| Support 3 (S3) | 4.98 | 5.18 | 5.04 | ||
| Support 4 (S4) | 4.95 |
